VCYT

Over the past six months, Veracyte's stock has increased by 29.31% over the past year, but recently declined by 4.1% in the past day, 12.2% in the past week, and 28.2% in the past 90 days. In Q1 2026, the company reported a 21% revenue increase to $139.1 million and a 26% testing revenue increase to $135.1 million year-over-year, with GAAP net income of $28.7 million, leading to an increased full-year revenue outlook. Q2 2026 saw total revenue of $150.3 million, a 15% year-over-year growth, and testing revenue up 19% to $145.7 million, with GAAP net income of $25.5 million, prompting another raise in full-year revenue guidance. On September 14, 2026, Veracyte acquired Convergent Genomics for $150 million, expanding its urology diagnostics portfolio. Several insiders, including the Global Chief Commercial Officer, Chief Scientific Officer, and Chief Financial Officer, sold shares in September 2026. Despite recent stock drops, analysts generally maintain a positive outlook with an average price target of $58.42, suggesting a potential 40.70% upside. Concerns about reimbursement for new products like Prosigna and potential de-emphasis of genomic tests for Decipher in low-risk active surveillance have been noted as factors impacting stock performance.